310 related articles for article (PubMed ID: 24128673)
21. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.
Harbeck N; Gluz O; Christgen M; Kates RE; Braun M; Küemmel S; Schumacher C; Potenberg J; Kraemer S; Kleine-Tebbe A; Augustin D; Aktas B; Forstbauer H; Tio J; von Schumann R; Liedtke C; Grischke EM; Schumacher J; Wuerstlein R; Kreipe HH; Nitz UA
J Clin Oncol; 2017 Sep; 35(26):3046-3054. PubMed ID: 28682681
[TBL] [Abstract][Full Text] [Related]
22. Precision Medicine and Targeted Therapies in Breast Cancer.
Greenwalt I; Zaza N; Das S; Li BD
Surg Oncol Clin N Am; 2020 Jan; 29(1):51-62. PubMed ID: 31757313
[TBL] [Abstract][Full Text] [Related]
23. Impact of Anti-HER2 Treatments Combined With Atezolizumab on the Tumor Immune Microenvironment in Early or Metastatic Breast Cancer: Results From a Phase Ib Study.
Hamilton EP; Kaklamani V; Falkson C; Vidal GA; Ward PJ; Patre M; Chui SY; Rotmensch J; Gupta K; Molinero L; Li Y; Emens LA
Clin Breast Cancer; 2021 Dec; 21(6):539-551. PubMed ID: 34154926
[TBL] [Abstract][Full Text] [Related]
24. Cardiotoxicity of novel HER2-targeted therapies.
Sendur MA; Aksoy S; Altundag K
Curr Med Res Opin; 2013 Aug; 29(8):1015-24. PubMed ID: 23692263
[TBL] [Abstract][Full Text] [Related]
25. Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy.
Li M; Li H; Liu F; Bi R; Tu X; Chen L; Ye S; Cheng X
J Ovarian Res; 2017 Feb; 10(1):9. PubMed ID: 28187748
[TBL] [Abstract][Full Text] [Related]
26. Targeted agents in ovarian cancer.
Kristedja TS; Morgan RJ; Cristea M
Womens Health (Lond); 2010 Sep; 6(5):679-94. PubMed ID: 20887168
[TBL] [Abstract][Full Text] [Related]
27. Evolution in the real-world therapeutic strategies in more than 20,000 women with breast cancer having received human epidermal growth factor receptor 2-targeted treatments: Results from the french personalized reimbursement model database (2011-2018).
Cottu P; Coudert B; Perol D; Doly A; Manson J; Aujoulat O; Barletta H; Chalabi N; Samelson L; Pivot X
Eur J Cancer; 2020 Dec; 141():209-217. PubMed ID: 33176232
[TBL] [Abstract][Full Text] [Related]
28. Current updates on precision therapy for breast cancer associated brain metastasis: Emphasis on combination therapy.
Raza M; Kumar N; Nair U; Luthra G; Bhattacharyya U; Jayasundar S; Jayasundar R; Sehrawat S
Mol Cell Biochem; 2021 Sep; 476(9):3271-3284. PubMed ID: 33886058
[TBL] [Abstract][Full Text] [Related]
29. Optimal sequencing of anti-HER2 therapy throughout the continuum of HER2-positive breast cancer: evidence and clinical considerations.
Harbeck N; Wuerstlein R
Drugs; 2013 Oct; 73(15):1665-80. PubMed ID: 24127221
[TBL] [Abstract][Full Text] [Related]
30. HER2-directed therapy for metastatic breast cancer.
Jelovac D; Emens LA
Oncology (Williston Park); 2013 Mar; 27(3):166-75. PubMed ID: 23687784
[TBL] [Abstract][Full Text] [Related]
31. [Targeted therapies in breast cancer].
Jerusalem G; Collignon J; Rorive A; Lifrange E; André C; Martin M; Maweja S; Coucke P
Rev Med Liege; 2011; 66(5-6):379-84. PubMed ID: 21826980
[TBL] [Abstract][Full Text] [Related]
32. Targeting HER2 in patient-derived xenograft ovarian cancer models sensitizes tumors to chemotherapy.
Harris FR; Zhang P; Yang L; Hou X; Leventakos K; Weroha SJ; Vasmatzis G; Kovtun IV
Mol Oncol; 2019 Feb; 13(2):132-152. PubMed ID: 30499260
[TBL] [Abstract][Full Text] [Related]
33. The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review.
Lau CH; Seow KM; Chen KH
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897700
[TBL] [Abstract][Full Text] [Related]
34. Targeted therapy in breast cancer: what's new?
Fang L; Barekati Z; Zhang B; Liu Z; Zhong X
Swiss Med Wkly; 2011; 141():w13231. PubMed ID: 21706452
[TBL] [Abstract][Full Text] [Related]
35. Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status.
Gadducci A; Guarneri V; Peccatori FA; Ronzino G; Scandurra G; Zamagni C; Zola P; Salutari V
J Ovarian Res; 2019 Jan; 12(1):9. PubMed ID: 30691488
[TBL] [Abstract][Full Text] [Related]
36. PARP inhibitors: A new era of targeted therapy.
Tangutoori S; Baldwin P; Sridhar S
Maturitas; 2015 May; 81(1):5-9. PubMed ID: 25708226
[TBL] [Abstract][Full Text] [Related]
37. Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer.
Meric-Bernstam F; Johnson AM; Dumbrava EEI; Raghav K; Balaji K; Bhatt M; Murthy RK; Rodon J; Piha-Paul SA
Clin Cancer Res; 2019 Apr; 25(7):2033-2041. PubMed ID: 30442682
[TBL] [Abstract][Full Text] [Related]
38. Cediranib in ovarian cancer: state of the art and future perspectives.
Ruscito I; Gasparri ML; Marchetti C; De Medici C; Bracchi C; Palaia I; Imboden S; Mueller MD; Papadia A; Muzii L; Panici PB
Tumour Biol; 2016 Mar; 37(3):2833-9. PubMed ID: 26753963
[TBL] [Abstract][Full Text] [Related]
39. The Evolving Landscape of HER2 Targeting in Breast Cancer.
Moasser MM; Krop IE
JAMA Oncol; 2015 Nov; 1(8):1154-61. PubMed ID: 26204261
[TBL] [Abstract][Full Text] [Related]
40. Current and emerging targeted therapies for metastatic breast cancer.
Perez EA; Spano JP
Cancer; 2012 Jun; 118(12):3014-25. PubMed ID: 22006669
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
